RankAlpha logo
Back to Rankings

ELTX

Elicio TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
A positive AMPLIFY-7P DFS readout followed by credible FDA Phase 3 alignment could move ELTX from a financing-driven microcap story toward a registrational oncology setup, with current valuation still below the sparse median target.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +37.2.
What can break
AMPLIFY-7P is the dominant driver and the readout is binary despite encouraging prior immune-response and IDMC signals.
Momentum
58
Value
41
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.00 · Bull $16.00 · Bear $6.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $15.50
Why
Momentum58 · Δ7d +37.2
Value41 · Δ7d +0.1
Sentiment42 · Δ7d -16.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
58
34% active weight
Current posture
7d trendImproving
Δ7d
+37.2
Δ21d
-3.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
42
33% active weight
Current posture
7d trendSoftening
Δ7d
-16.5
Δ21d
+3.3
Why this grade

Composite grade D. Momentum 58.3 / Value 41.1 / Sentiment 41.6

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$231.32M
Beta
-
Shares Out
17.49M
P/E (TTM) · Derived
-3.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.04
Rev YoY
-
EPS YoY
+56.4%
Gross Margin
-
Op Margin
-
Net Debt
$2.42M
Current Ratio
3.29
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology